[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with a constellation of symptoms highly suggestive of a specific autoimmune neurological syndrome. Let's break down the key features:\n1.  Progressive sleep dysfunction: Dream enactment is a hallmark of REM sleep behavior disorder (RBD). Non-REM parasomnias and daytime somnolence further support a significant sleep disorder.\n2.  Neurological deficits: Gait instability indicates cerebellar or other motor pathway involvement. Mild cognitive decline suggests impact on brain function.\n3.  Imaging and PSG findings: Polysomnography confirms RBD and non-REM parasomnias. Brain MRI shows mild cerebellar atrophy, consistent with the gait instability.\n4.  Age: 68 years old.\n5.  Nocturnal stridor: This can be associated with bulbar dysfunction or respiratory involvement, which can occur in certain neurological conditions.\n\nNow let's consider the antibodies:\n\n*   A. Anti-Hu antibody: Typically associated with paraneoplastic syndromes (especially small cell lung cancer). While it can cause cerebellar degeneration and sensory neuropathy, prominent sleep disorders like RBD are not the primary feature.\n*   B. Anti-Yo antibody: Primarily associated with paraneoplastic cerebellar degeneration, most often seen in women with gynecological cancers. Severe ataxia is the main symptom, with sleep disturbances being uncommon.\n*   C. Anti-IgLON5 antibody: This antibody is characteristic of a rare autoimmune disorder that often presents with progressive sleep abnormalities (including RBD and non-REM parasomnias), bulbar and oculomotor dysfunction, ataxia, cognitive decline, sleep-related breathing disturbances (which could manifest as nocturnal stridor), and sometimes parkinsonism or chorea. The syndrome often occurs in older adults and can show atrophy in the cerebellum, brainstem, and thalamus. This description fits the patient's presentation very closely.\n*   D. Anti-Ma2 antibody: Associated with a form of limbic encephalitis and brainstem encephalitis, often paraneoplastic (e.g., testicular cancer in men). Symptoms include amnesia, confusion, seizures, and oculomotor palsy. While cognitive and brainstem symptoms exist, overt RBD and prominent cerebellar signs are not typical hallmarks.\n*   E. Anti-NMDA receptor antibody: This is a common cause of autoimmune encephalitis, especially in younger women. Typical symptoms include psychosis, seizures, movement disorders (dyskinetic), autonomic instability, and altered consciousness. While sleep disturbances can occur, the pattern of progressive RBD, gait instability, and cerebellar atrophy in an older male patient is not typical for anti-NMDA receptor encephalitis.\n\nThe combination of prominent sleep disorders (RBD, non-REM parasomnias), gait instability/cerebellar atrophy, cognitive decline, and nocturnal stridor in a 68-year-old man strongly points towards a syndrome associated with Anti-IgLON5 antibodies.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Rationale Analysis:\nThe patient presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery, with a mildly elevated serum hCG and an intrauterine mass on MRI. The key pathological findings from the endometrial biopsy are:\n1.  Sheets of intermediate trophoblastic cells: This points towards a trophoblastic tumor derived from these specific cells, differentiating it from tumors primarily composed of cytotrophoblasts and syncytiotrophoblasts (like choriocarcinoma).\n2.  Eosinophilic cytoplasm and low mitotic index: These features are consistent with intermediate trophoblasts and suggest a less aggressive proliferative behavior than choriocarcinoma.\n3.  Immunohistochemical staining:\n    *   Strongly positive for hPL (human placental lactogen): hPL is produced by syncytiotrophoblasts and intermediate trophoblasts. Strong positivity supports a trophoblastic origin, particularly intermediate trophoblasts.\n    *   Negative for hCG (human chorionic gonadotropin): This is a critical finding. Most gestational trophoblastic diseases, including hydatidiform moles, invasive moles, and choriocarcinomas, are characterized by significantly elevated hCG levels due to abundant syncytiotrophoblast proliferation. Low or undetectable hCG in the presence of hPL positivity is highly suggestive of a tumor where intermediate trophoblasts dominate and syncytiotrophoblasts are minimal or absent.\n\nEvaluating the options:\nA.  Choriocarcinoma: Typically has high hCG, high mitotic index, and sheets of atypical cytotrophoblasts and syncytiotrophoblasts, not primarily intermediate trophoblasts. This diagnosis is unlikely given the low hCG and negative marker.\nB.  Placental site trophoblastic tumor (PSTT): This rare tumor arises from intermediate trophoblasts. Histologically, it consists of sheets or nests of intermediate trophoblasts with eosinophilic cytoplasm, a low mitotic index, and often local invasion. Functionally, PSTTs produce hPL, and hCG levels can be low or undetectable because syncytiotrophoblasts are sparse. The clinical presentation (late bleeding after pregnancy) and the pathological findings (intermediate trophoblasts, eosinophilic cytoplasm, low mitosis, strong hPL, negative hCG) are classic for PSTT.\nC.  Epithelioid trophoblastic tumor (ETT): ETTs are another rare variant of GTD. They are characterized by nests of discohesive epithelioid-like intermediate trophoblastic cells. While hPL can be positive, the morphology described ('sheets of intermediate trophoblastic cells') is more typical of PSTT, and the 'epithelioid' morphology is not mentioned.\nD.  Persistent hydatidiform mole: This involves retained molar tissue. Histologically, hydropic villi are a hallmark, along with varying degrees of trophoblastic proliferation. hCG is typically significantly elevated. The biopsy findings described here are not typical of a hydatidiform mole.\nE.  Invasive mole: This is a hydatidiform mole that invades the myometrium. It would typically show hydropic villi and elevated hCG. The biopsy findings here do not fit this diagnosis.\n\nTherefore, the combination of intermediate trophoblastic cell proliferation, low mitotic index, strong hPL positivity, and negative hCG strongly favors Placental site trophoblastic tumor. The late presentation also fits this diagnosis.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient presents with severe hypertrophic cardiomyopathy, ventricular pre-excitation (WPW pattern), recurrent syncope, and pre-excited atrial fibrillation that is refractory to maximal medical therapy in the context of Danon disease. Danon disease is associated with a high risk of sudden cardiac death, primarily from arrhythmias originating from accessory pathways or intrinsic myocardial disease. The presence of pre-excited atrial fibrillation with rapid ventricular response through accessory pathways is a life-threatening condition.\n\nLet's evaluate the options:\nA. Initiate flecainide therapy: Flecainide is a Class Ic antiarrhythmic. While it can suppress accessory pathways, it also significantly depresses conduction through the AV node. In a patient with pre-excited atrial fibrillation, using a drug that primarily blocks the AV node while still allowing conduction down the accessory pathway can lead to a dangerously slow AV nodal rate and a very rapid ventricular rate through the accessory pathway, thereby increasing the risk of ventricular fibrillation and sudden cardiac death. Furthermore, Class Ic drugs are generally contraindicated in patients with significant structural heart disease like hypertrophic cardiomyopathy due to increased proarrhythmia risk.\n\nB. Perform catheter ablation of all accessory pathways: Catheter ablation is the definitive treatment for symptomatic accessory pathways. In patients with WPW syndrome who experience life-threatening arrhythmias such as pre-excited atrial fibrillation, rapid ventricular response, or recurrent syncope, catheter ablation is the recommended treatment. Given that the patient has recurrent pre-excited atrial fibrillation and has failed maximal medical therapy, ablation of the identified accessory pathways is the most appropriate next step to eliminate the arrhythmogenic substrate and reduce the risk of sudden cardiac death.\n\nC. Increase beta-blocker dosage: Beta-blockers are useful for controlling symptoms of hypertrophic cardiomyopathy and can slow conduction through the AV node, thereby slowing the ventricular rate during atrial fibrillation. However, they do not eliminate the accessory pathway. While part of optimal medical management, increasing beta-blocker dosage alone is unlikely to resolve the recurrent pre-excited atrial fibrillation when maximal therapy has already failed and is not a curative solution for the underlying problem (accessory pathways).\n\nD. Evaluate for heart transplantation: Heart transplantation is indicated for end-stage heart failure or severe, refractory symptoms of cardiomyopathy. While Danon disease can lead to severe cardiomyopathy, the immediate primary concern highlighted in this scenario is the life-threatening arrhythmia due to accessory pathways. Ablation is the priority intervention for symptomatic accessory pathways, especially those causing pre-excited atrial fibrillation, before considering transplantation.\n\nE. Implant a dual-chamber pacemaker: A pacemaker is primarily used to treat bradyarrhythmias or for cardiac resynchronization therapy in heart failure. It does not address the presence of accessory pathways or the risk of pre-excited arrhythmias. In fact, inappropriate pacing in the presence of accessory pathways could potentially lead to complex electrophysiological interactions and adverse outcomes.\n\nConsidering the patient's presentation of recurrent, severe, life-threatening arrhythmias (pre-excited atrial fibrillation) due to identified distinct accessory pathways, refractory to maximal medical therapy, catheter ablation of these pathways is the most definitive and appropriate next management step.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-004", "question": "A 42-year-old woman with multiple sclerosis on natalizumab for 30 months develops subacute cognitive decline over 3 weeks. Her JCV antibody index is 2.8. Brain MRI reveals new non-enhancing subcortical white matter lesions without mass effect. CSF JCV PCR is positive. Which intervention is most critical to improve survival?", "options": ["A) Continue natalizumab with close monitoring", "B) Switch directly to ocrelizumab", "C) Initiate immediate plasma exchange", "D) Start mirtazapine 30 mg daily", "E) Begin mefloquine 250 mg weekly"], "answer": "C", "answer_index": 2, "explanation": "Natalizumab-associated progressive multifocal leukoencephalopathy requires immediate drug discontinuation and plasma exchange to rapidly clear the monoclonal antibody, preventing immune reconstitution inflammatory syndrome (IRIS) and improving survival. Continuing or switching immunosuppression is contraindicated. Mirtazapine and mefloquine have been investigated but lack evidence of benefit. Plasma exchange is the only intervention shown to alter mortality.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with symptoms and findings highly suggestive of progressive multifocal leukoencephalopathy (PML), a serious opportunistic infection caused by the John Cunningham virus (JCV). The patient is on natalizumab, a medication known to increase the risk of PML. The positive JCV PCR in the cerebrospinal fluid confirms the diagnosis of PML.\n\nThe management of natalizumab-associated PML is primarily focused on removing the offending immunosuppressant drug and allowing the immune system to recover and fight the virus. Natalizumab has a long half-life, and its continued presence in the body exacerbates the infection.\n\nLet's evaluate the options:\nA.  Continue natalizumab with close monitoring: This is contraindicated. Continuing natalizumab would worsen PML and lead to severe neurological damage or death.\nB.  Switch directly to ocrelizumab: Ocrelizumab is also an immunosuppressant and may carry its own risks of PML. Switching to another immunosuppressant without addressing the current PML is inappropriate and potentially harmful.\nC.  Initiate immediate plasma exchange: Plasma exchange is a procedure to rapidly remove natalizumab from the bloodstream. Given natalizumab's long half-life, this intervention accelerates the drug's clearance, promotes immune reconstitution, and is considered critical for improving survival in patients with natalizumab-associated PML. This is a well-established management strategy.\nD.  Start mirtazapine 30 mg daily: Mirtazapine is an antidepressant and has no role in the direct management of PML.\nE.  Begin mefloquine 250 mg weekly: Mefloquine is not a standard or proven treatment for PML.\n\nThe most critical intervention to improve survival in this scenario is the prompt and effective removal of natalizumab. Plasma exchange significantly accelerates this process compared to natural clearance alone, making it the most critical intervention among the choices provided for improving survival.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-005", "question": "A 58-year-old man presents with a 5-year history of chronic urticarial rash, recurrent fevers, debilitating bone pain, and monoclonal IgM kappa on serum protein electrophoresis. Symptoms are refractory to high-dose H1/H2 antihistamines. Laboratory studies reveal markedly elevated ESR and CRP. Which cytokine is the primary therapeutic target for this condition?", "options": ["A) Interleukin-1", "B) Interleukin-6", "C) Interleukin-17", "D) Tumor necrosis factor-alpha", "E) Interferon-gamma"], "answer": "A", "answer_index": 0, "explanation": "Schnitzler syndrome is an autoinflammatory disease driven by NLRP3 inflammasome activation with overproduction of IL-1β. Anakinra, an IL-1 receptor antagonist, is first-line therapy and induces rapid remission. While IL-6 and TNF-alpha may be elevated, they are not the primary pathogenic cytokines. IL-17 and interferon-gamma are not central to the disease mechanism.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with a constellation of symptoms including chronic urticarial rash, recurrent fevers, debilitating bone pain, and a monoclonal IgM kappa protein detected on serum protein electrophoresis. These findings, particularly the monoclonal IgM and systemic symptoms, are highly suggestive of Waldenstrom's macroglobulinemia (WM), a lymphoplasmacytic lymphoma. The elevated ESR and CRP indicate significant inflammation. The refractoriness to antihistamines suggests the urticaria is not solely histamine-mediated but part of a systemic inflammatory process or B-cell malignancy.\n\nLet's evaluate the role of the given cytokines in the pathogenesis of WM and associated inflammation:\n\n*   Interleukin-6 (IL-6): IL-6 is a pleiotropic cytokine known to promote the survival, proliferation, and differentiation of B lymphocytes, including malignant B cells in lymphomas like WM. Elevated levels of IL-6 are commonly found in patients with WM and are associated with disease activity and prognosis. IL-6 acts through autocrine and paracrine loops to sustain the growth of lymphoplasmacytic cells in WM. Therapeutic agents targeting IL-6 (e.g., siltuximab, an IL-6 monoclonal antibody, or tocilizumab, an IL-6 receptor antagonist) have shown efficacy in related lymphoproliferative disorders like Castleman disease and are explored in WM. Given IL-6's central role in driving the proliferation of malignant B cells in WM, it is a key pathogenetic cytokine and a significant therapeutic target.\n\n*   Tumor necrosis factor-alpha (TNF-alpha): TNF-alpha is a potent pro-inflammatory cytokine involved in various inflammatory conditions and can contribute to cell survival and proliferation in some cancers. While it can contribute to systemic inflammation and symptoms like fever and bone pain, its role as a primary driver of B-cell proliferation specifically in WM is generally considered less direct than that of IL-6.\n\n*   Interleukin-1 (IL-1): IL-1 is another pro-inflammatory cytokine involved in fever, inflammation, and bone resorption. It plays a role in various inflammatory diseases, but like TNF-alpha, its direct contribution to the proliferation of WM cells is not as central as IL-6.\n\n*   Interleukin-17 (IL-17): IL-17 is primarily involved in host defense against pathogens and in inflammatory and autoimmune diseases. It is not typically considered a primary cytokine target for WM pathogenesis.\n\n*   Interferon-gamma (IFN-gamma): IFN-gamma is important in antiviral and antitumor immunity, and in activating macrophages. While it plays a role in immune responses, it is not a principal cytokine target for WM.\n\nConsidering the options, IL-6 is the cytokine most directly implicated in the pathogenesis of Waldenstrom's macroglobulinemia by driving the proliferation and survival of the malignant lymphoplasmacytic cells. Therefore, it represents a primary therapeutic target for this condition.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-006", "question": "A 35-year-old man with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, and cerebellar ataxia is diagnosed with cerebrotendinous xanthomatosis. Serum cholestanol level is markedly elevated. Which treatment modality has been shown to halt neurologic progression in this disorder?", "options": ["A) High-intensity statin therapy", "B) Chenodeoxycholic acid supplementation", "C) Weekly LDL apheresis", "D) Ezetimibe monotherapy", "E) Coenzyme Q10 supplementation"], "answer": "B", "answer_index": 1, "explanation": "Cerebrotendinous xanthomatosis results from CYP27A1 deficiency, causing cholestanol accumulation in neural tissue. Chenodeoxycholic acid inhibits cholesterol 7α-hydroxylase, reducing cholestanol synthesis and stabilizing neurologic function. Statins, ezetimibe, and LDL apheresis do not effectively lower central nervous system cholestanol. Coenzyme Q10 is used for mitochondrial disorders, not this condition.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe question asks about the treatment modality that has been shown to halt neurologic progression in cerebrotendinous xanthomatosis (CTX). CTX is caused by a defect in the CYP27A1 gene, leading to reduced synthesis of bile acids and accumulation of cholesterol and cholestanol.\n\nLet's evaluate the options:\nA. High-intensity statin therapy: Statins are primarily used to lower LDL cholesterol. While cholesterol accumulation is an issue in CTX, statins do not directly address the underlying bile acid synthesis defect or the accumulation of cholestanol in a way that halts neurologic progression.\nB. Chenodeoxycholic acid supplementation: Chenodeoxycholic acid (CDCA) is a primary bile acid. Supplementing with CDCA bypasses the enzyme deficiency (sterol 27-hydroxylase), restores bile acid synthesis, reduces cholestanol accumulation, and has been demonstrated in studies to halt or slow neurologic progression, especially when initiated early.\nC. Weekly LDL apheresis: LDL apheresis removes LDL cholesterol from the blood. While it lowers cholesterol levels, it is not considered a primary treatment for CTX and does not address the root cause of the metabolic defect leading to neurologic damage.\nD. Ezetimibe monotherapy: Ezetimibe blocks cholesterol absorption in the intestine. Similar to statins, it targets cholesterol reduction but is not the specific treatment for halting neurologic progression in CTX.\nE. Coenzyme Q10 supplementation: While some studies have explored CoQ10 for potential benefits related to mitochondrial function in CTX, it is not the established primary treatment shown to halt neurologic progression.\n\nChenodeoxycholic acid supplementation is the universally recognized cornerstone therapy for CTX shown to halt neurologic progression.\n\nThe answer is B"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-007", "question": "A 16-year-old girl presents with cyclic, worsening right pelvic pain for 6 months, occurring with each menses. She reports normal menstrual bleeding. Pelvic ultrasound reveals a didelphic uterus with a 5 cm right hematocolpos and a normal left uterine horn. Renal ultrasound demonstrates absence of the right kidney. Which congenital anomaly best explains this presentation?", "options": ["A) Mayer-Rokitansky-Küster-Hauser syndrome", "B) OHVIRA syndrome", "C) Complete androgen insensitivity syndrome", "D) Transverse vaginal septum", "E) Imperforate hymen"], "answer": "B", "answer_index": 1, "explanation": "OHVIRA (Obstructed Hemivagina with Ipsilateral Renal Agenesis) syndrome is characterized by a didelphic uterus with obstructed hemivagina causing hematocolpos and ipsilateral renal agenesis. Patients have normal menses from the patent uterine horn. MRKH syndrome involves uterine agenesis. CAIS affects 46,XY individuals. Transverse vaginal septum and imperforate hymen occur with a normal uterus and kidneys.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with cyclic pelvic pain, a didelphic uterus with a right hematocolpos (indicating obstruction of the right vaginal canal or cervix, leading to menstrual blood accumulation), and absence of the right kidney.\n\nLet's analyze the options:\nA. Mayer-Rokitansky-Küster-Hauser syndrome (MRKH) is characterized by the absence or severe hypoplasia of the uterus and vagina. This patient has a didelphic uterus, so this is incorrect.\nB. OHVIRA syndrome (Obstructed Hemivagina and Ipsilateral Renal Anomaly) is a condition characterized by a didelphic uterus, an obstructed hemivagina (leading to hematocolpos or hematometra), and an ipsilateral renal anomaly (usually renal agenesis). This description perfectly matches the patient's findings: didelphic uterus, obstruction of the right hemivagina causing hematocolpos, and ipsilateral renal agenesis (absence of the right kidney).\nC. Complete androgen insensitivity syndrome (CAIS) results in individuals with XY chromosomes who are phenotypically female but lack internal female reproductive organs like a uterus and ovaries, having testes instead. This patient has a uterus and menstrual bleeding, so this is incorrect.\nD. Transverse vaginal septum is an obstruction within the vagina. While it can cause hematocolpos and pain, it doesn't inherently include a didelphic uterus or ipsilateral renal agenesis as part of the definition. The presence of a didelphic uterus and the specific association with renal agenesis points more towards OHVIRA syndrome.\nE. Imperforate hymen is a complete blockage of the vaginal opening by the hymen. Similar to a transverse vaginal septum, it can cause hematocolpos and pain, but the presence of a didelphic uterus and ipsilateral renal agenesis is not a characteristic feature of isolated imperforate hymen.\n\nThe combination of a didelphic uterus, an obstructed hemivagina, and ipsilateral renal agenesis is specifically defined as OHVIRA syndrome.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-008", "question": "A 62-year-old man with a HeartMate 3 left ventricular assist device presents with acute onset of dark urine, fatigue, and dizziness. Laboratory studies demonstrate LDH 2,800 U/L and plasma free hemoglobin 80 mg/dL. Device interrogation shows increased power consumption with intermittent spikes. Transthoracic echocardiography suggests inflow cannula obstruction. What is the most appropriate immediate management?", "options": ["A) Increase warfarin target INR to 3.5-4.0", "B) Initiate intravenous unfractionated heparin infusion", "C) Administer intraventricular alteplase 25 mg", "D) Deliver intrapump alteplase 10 mg via percutaneous catheter", "E) Proceed to emergent surgical pump exchange"], "answer": "D", "answer_index": 3, "explanation": "HeartMate 3 pump thrombosis is managed with low-dose intrapump alteplase (10 mg) delivered via percutaneous catheter directly into the device, which has shown high success rates. Systemic thrombolysis or intraventricular administration risks hemorrhagic stroke. Increasing anticoagulation is insufficient for established thrombosis. Surgical exchange is reserved for thrombolysis failure or hemodynamic collapse.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with signs and symptoms highly suggestive of hemolysis (dark urine, fatigue, dizziness, elevated LDH, elevated plasma free hemoglobin) likely secondary to left ventricular assist device (LVAD) dysfunction. The increased power consumption with intermittent spikes and suggestion of inflow cannula obstruction on echocardiography point towards a problem within the pump, most commonly thrombosis.\n\nLet's evaluate the options:\nA. Increasing warfarin target INR to 3.5-4.0: While anticoagulation is crucial, arbitrarily increasing the INR to such a high target without addressing the acute pump issue is not the most appropriate *immediate* step, and could increase bleeding risk.\nB. Initiating intravenous unfractionated heparin infusion: Similar to warfarin, this is an anticoagulation strategy and does not directly address a mechanical obstruction or potential thrombus within the pump causing pump dysfunction.\nC. Administering intraventricular alteplase 25 mg: \"Intraventricular\" is vague in the context of an LVAD. If it implies administration into the pump, it's a form of thrombolysis. However, the dose and route are less specific than option D.\nD. Deliver intrapump alteplase 10 mg via percutaneous catheter: This describes a specific, recognized intervention for suspected pump thrombosis in LVADs, particularly HeartMate 3. Intrapump thrombolysis directly targets thrombus formation within the pump, which is a common cause of inflow obstruction, pump dysfunction, and hemolysis. This is often the first-line treatment attempted before surgical intervention.\nE. Proceed to emergent surgical pump exchange: This is a definitive treatment but is more invasive and typically considered if less invasive methods like thrombolysis are unsuccessful or contraindicated, or if there is evidence of severe mechanical failure beyond thrombus.\n\nGiven the constellation of symptoms, laboratory findings, and device findings, suspecting pump thrombosis leading to obstruction and hemolysis is reasonable. Intrapump thrombolysis is the most appropriate immediate management to attempt to resolve the pump dysfunction and hemolysis.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical presentation of subacute onset of severe headaches, focal seizures, and left hemiparesis in a 55-year-old immunocompetent gardener, coupled with MRI findings of multiple ring-enhancing lesions with surrounding edema, strongly suggests an intracranial space-occupying lesion. The CSF analysis revealing lymphocytic pleocytosis and negative bacterial, fungal, and mycobacterial cultures narrows down the differential diagnoses.\n\nLet's analyze the options in the context of the differential diagnoses:\n\n*   Differential Diagnoses: Given the findings, key considerations include:\n    1.  Neurocysticercosis: This parasitic infection from *Taenia solium* larvae is a common cause of seizures and multiple ring-enhancing lesions in the brain, especially in endemic areas or in individuals with exposure history, and can occur in immunocompetent hosts.\n    2.  Toxoplasmosis: More common in immunocompromised individuals, but can occur in immunocompetent persons and present with ring-enhancing lesions and focal deficits.\n    3.  Tuberculoma: *Mycobacterium tuberculosis* can cause granulomas that appear as ring-enhancing lesions, often with lymphocytic CSF.\n    4.  Brain abscess (bacterial): While possible, the lymphocytic pleocytosis makes typical bacterial abscess less likely. Negative cultures further reduce this probability, though not entirely excluding it.\n    5.  Fungal infections: Certain fungi (e.g., Cryptococcus, Aspergillus) can cause ring-enhancing lesions, but negative fungal cultures make this less likely as an initial empiric choice without further evidence.\n    6.  Neoplastic lesions: Metastases or primary brain tumors can present with ring-enhancing lesions, but the subacute onset and CSF findings might point more towards an infectious/inflammatory process.\n\n*   Evaluation of Options:\n    *   A. Liposomal amphotericin B: This is an antifungal agent. It would be appropriate for fungal infections, but negative fungal cultures make it a less likely *empiric* choice here.\n    *   B. Albendazole plus miltefosine:\n        *   Albendazole is a broad-spectrum antiparasitic, and the drug of choice for neurocysticercosis.\n        *   Miltefosine is an antiparasitic drug primarily used for leishmaniasis, but it also has activity against other protozoa and helminths, and research supports its investigation and potential use in certain parasitic CNS infections, including neurocysticercosis, sometimes in combination.\n        Given the strong suspicion for neurocysticercosis (or other parasitic infections) based on MRI and CSF findings, an antiparasitic regimen is highly appropriate. This option is the only one targeting parasitic etiologies.\n    *   C. Vancomycin plus ceftriaxone plus dexamethasone: This is empiric therapy for bacterial meningitis. The lymphocytic pleocytosis in the CSF makes typical bacterial meningitis unlikely. While dexamethasone addresses inflammation, the antibiotics are not directed at the most probable causes.\n    *   D. Ganciclovir plus foscarnet: These are antiviral medications used for Cytomegalovirus (CMV). CMV neurological disease typically occurs in immunocompromised individuals and usually does not present with multiple ring-enhancing lesions in this manner.\n    *   E. Voriconazole: This is an antifungal agent. Similar to option A, it is less likely to be the *most appropriate empiric* therapy given the negative fungal cultures.\n\n*   Conclusion: The constellation of findings, particularly the multiple ring-enhancing lesions in an immunocompetent host alongside lymphocytic pleocytosis and negative standard cultures, strongly favors a parasitic etiology like neurocysticercosis. While the combination of albendazole and miltefosine might seem specific, albendazole is the cornerstone of neurocysticercosis treatment, and research supports the investigation of miltefosine for certain parasitic CNS conditions. Therefore, this option represents the most appropriate *empiric* therapy targeting the most likely category of disease.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a constellation of symptoms including recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory findings show low IgM, elevated IgA, and negative ANCA. Genetic testing revealing biallelic loss-of-function mutations in ADA2 is diagnostic for Deficiency of Adenosine Deaminase 2 (DADA2). DADA2 is an inherited autoinflammatory disorder characterized by systemic inflammation leading to vasculitis and other autoimmune manifestations.\n\nLet's evaluate the treatment options in the context of DADA2:\n\nA. High-dose systemic glucocorticoids: Glucocorticoids can suppress inflammation and may provide temporary symptomatic relief for the fevers and vasculitis. However, they do not address the underlying genetic defect and are associated with significant long-term side effects, especially in children. They are often used as initial therapy but are not considered the most effective long-term biologic treatment.\n\nB. Intravenous cyclophosphamide: Cyclophosphamide is a potent immunosuppressant used for severe vasculitis. While it might be used in severe, refractory cases mimicking polyarteritis nodosa, it has significant toxicity. It is not the primary or most effective therapy for the autoinflammatory aspect of DADA2.\n\nC. Etanercept: Etanercept is a tumor necrosis factor (TNF) inhibitor. Studies and clinical experience have shown that TNF inhibitors are generally not effective for DADA2 and can sometimes even worsen the condition.\n\nD. Anakinra: Anakinra is an interleukin-1 (IL-1) receptor antagonist. DADA2 is an autoinflammatory disease in which IL-1 is a key pro-inflammatory cytokine. Evidence from case series and clinical trials suggests that IL-1 blockade with agents like anakinra and canakinumab is highly effective in controlling the systemic inflammation, fevers, and preventing vascular complications in DADA2.\n\nE. Rituximab: Rituximab is a B-cell depleting antibody. While B-cell dysregulation can occur, the primary pathology in DADA2 is related to ADA2 deficiency and a broader inflammatory cascade, making B-cell depletion less likely to be the most effective primary biologic therapy compared to targeting IL-1.\n\nConsidering the current understanding and treatment guidelines for DADA2, IL-1 blockade, such as with anakinra, is considered one of the most effective biologic therapies for managing the inflammatory manifestations and preventing disease progression when hematopoietic stem cell transplantation (curative but not an option here) is not pursued or feasible immediately.\n\nThe final answer is $\\boxed{D}$."}]